Rosetta shares up on heavy volume

Shares of nano cap Rosetta Genomics (ROSG +15.2%) pop 11% on twice normal volume.

Company reports the publication of a study suggesting the predictive role of miRNA's in platelets in chronic heart failure patients with atrial fibrillation (AF). The results revealed a 3.2-fold lower miR-150 expression in the platelets of patients with AF compared to those without AF. Patients with AF generally have poor prognoses.

The use of miRNA biomarkers in the management of heart disease is a major research area for Rosetta. It plans to launch an AF assay in 2017.

From other sites
Comments (1)
  • lili-usa
    , contributor
    Comments (6) | Send Message
    ROSG heading for $20.


    I think we might see even higher volume by Thurs
    4 Mar 2014, 05:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs